FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2424076532> ?p ?o ?g. }

• W2424076532 abstract "Currently, Indonesia is in the 5th rank of the highest tuberculosis prevalence over the world. The treatment of tuberculosis is going complicated due to the side effect experienced by the patients. The four combination of antituberculosis agent used in minimally 6 months of treatment could stimulate the hepatotoxicity as the one of the dominant side effect in tuberculosis treatment. Thus, it is important to do the Therapeutic Drug Monitoring (TDM) to optimize the tuberculosis treatment. This study is aimed to validate the TDM of pyrazinamide in human plasma using High Performance Liquid Chromatography-UV. We recruited 6 TB patients in the validation of pyrazinamide study. The C18 column shim-pack VP-ODS (250 mm x 4.6 mm, id 5 µm) and aquabidest-acetonitrile as mobile phase were applied in this study. We used Shimadzu HPLC system with a model AT LC20 LC 10AT pump, detector SPD 20A and LC solution software. We performed the analysis for linearity, system appropriateness, accuracy and recovery to develop the validation method. This study has been approved by National Ethics Committee of Health Research. Our study shows that the linearity is good with value of r2> 0.99 and the equation y = 16740.876x - 2953.615. The CV TR and CV peak area for system suitability are 1.46% and 0.29%, respectively. The LoD and LoQ value are 2.532 and 7.672 µg/mL, respectively. The accuracy on the concentration of 1.00, 8.00, 60.00 ug/ml are 108.80 %, 92.57 % and 100.98 %, respectively for intraday accuracy and 103.18 %, 92.44%, and 94.94%, respectively for interday accuracy. Furthermore, the precision on the concentration of 1.00, 8.00, 60.00 ug/ml are 1.17%, 3.57%, 3.32%, respectively for intraday precision and 3.66%, 1.37% and 1.59%, respectively for interday precision. In conclusion, the method which we applied in this study was sensitive and reliable for routine TDM of pyrazinamide." @default.
• W2424076532 created "2016-06-24" @default.
• W2424076532 creator A5014461768 @default.
• W2424076532 creator A5045110424 @default.
• W2424076532 creator A5061643845 @default.
• W2424076532 creator A5066794334 @default.
• W2424076532 creator A5074545108 @default.
• W2424076532 date "2016-01-01" @default.
• W2424076532 modified "2023-10-03" @default.
• W2424076532 title "Validation of pyrazinamide in human plasma using Hplc-Uv for therapeutic drug monitoring" @default.
• W2424076532 cites W1971210149 @default.
• W2424076532 cites W2021702829 @default.
• W2424076532 cites W2025330324 @default.
• W2424076532 cites W2027522534 @default.
• W2424076532 cites W2068885767 @default.
• W2424076532 cites W2070931526 @default.
• W2424076532 cites W2072638201 @default.
• W2424076532 cites W2116895135 @default.
• W2424076532 cites W2147213334 @default.
• W2424076532 cites W2416178142 @default.
• W2424076532 cites W2418210342 @default.
• W2424076532 doi "https://doi.org/10.1063/1.4953956" @default.
• W2424076532 hasPublicationYear "2016" @default.
• W2424076532 type Work @default.
• W2424076532 sameAs 2424076532 @default.
• W2424076532 citedByCount "1" @default.
• W2424076532 countsByYear W24240765322018 @default.
• W2424076532 crossrefType "proceedings-article" @default.
• W2424076532 hasAuthorship W2424076532A5014461768 @default.
• W2424076532 hasAuthorship W2424076532A5045110424 @default.
• W2424076532 hasAuthorship W2424076532A5061643845 @default.
• W2424076532 hasAuthorship W2424076532A5066794334 @default.
• W2424076532 hasAuthorship W2424076532A5074545108 @default.
• W2424076532 hasBestOaLocation W24240765322 @default.
• W2424076532 hasConcept C142724271 @default.
• W2424076532 hasConcept C179998833 @default.
• W2424076532 hasConcept C185592680 @default.
• W2424076532 hasConcept C2778607973 @default.
• W2424076532 hasConcept C2780035454 @default.
• W2424076532 hasConcept C2780272996 @default.
• W2424076532 hasConcept C2780459521 @default.
• W2424076532 hasConcept C2781069245 @default.
• W2424076532 hasConcept C43617362 @default.
• W2424076532 hasConcept C71924100 @default.
• W2424076532 hasConcept C98274493 @default.
• W2424076532 hasConceptScore W2424076532C142724271 @default.
• W2424076532 hasConceptScore W2424076532C179998833 @default.
• W2424076532 hasConceptScore W2424076532C185592680 @default.
• W2424076532 hasConceptScore W2424076532C2778607973 @default.
• W2424076532 hasConceptScore W2424076532C2780035454 @default.
• W2424076532 hasConceptScore W2424076532C2780272996 @default.
• W2424076532 hasConceptScore W2424076532C2780459521 @default.
• W2424076532 hasConceptScore W2424076532C2781069245 @default.
• W2424076532 hasConceptScore W2424076532C43617362 @default.
• W2424076532 hasConceptScore W2424076532C71924100 @default.
• W2424076532 hasConceptScore W2424076532C98274493 @default.
• W2424076532 hasLocation W24240765321 @default.
• W2424076532 hasLocation W24240765322 @default.
• W2424076532 hasOpenAccess W2424076532 @default.
• W2424076532 hasPrimaryLocation W24240765321 @default.
• W2424076532 hasRelatedWork W1971995528 @default.
• W2424076532 hasRelatedWork W1991969313 @default.
• W2424076532 hasRelatedWork W2013924808 @default.
• W2424076532 hasRelatedWork W2015025206 @default.
• W2424076532 hasRelatedWork W2051789873 @default.
• W2424076532 hasRelatedWork W2053849879 @default.
• W2424076532 hasRelatedWork W2127140200 @default.
• W2424076532 hasRelatedWork W2567767604 @default.
• W2424076532 hasRelatedWork W2951688912 @default.
• W2424076532 hasRelatedWork W927468184 @default.
• W2424076532 isParatext "false" @default.
• W2424076532 isRetracted "false" @default.
• W2424076532 magId "2424076532" @default.
• W2424076532 workType "article" @default.